申请人:Taiho Pharmaceutical Co., Ltd.
公开号:EP3632443A1
公开(公告)日:2020-04-08
An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I):
wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.
一种抗肿瘤制剂,包括一种具有 LSD1 抑制活性的联苯化合物或其盐类,以及一种或多种其他抗肿瘤制剂,这些制剂联合使用,化合物由式 (I) 表示:
其中环 A、环 B、R1 至 R6、l、m 和 n 如说明书中所定义。